louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02328651: Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth Disease
Official title: Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Handfoot-mouth Disease
Keywords: Mild and Moderate Severe Patients With hand_foot-mouth Disease
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
Collaborators: name: Weihai Rensheng Pharmacy
First posted: 2014-12-31
Enrollment: 24
Sex: ALL
Minimum age (years): 1
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a single-blinded randomized trial aiming to evaluate the effectiveness of Xiaoer Jiebiao Oral liquid in combination with Ribavirin treatment on patients with hand-foot-mouth disease compared with the controlgroup that recieve only libavirin treatment.


Eligibility criteria: Inclusion Criteria:subjects should meet all of the following

* diagnosed as hand-foot-mouth disease grade I or grade II;
* body temperature at admission T\>38℃，fever length\<48 hours;
* no need for hormonotherapy or immunoglobulin therapy.
* signed written informed consent form

Exclusion Criteria:subjects should be excluded if meet any of the following

* with history of any heart, lung, kidney or liver diseases; under any hormonotherapy, immunoglobulin therapy or any other therapy.

Primary outcomes:
measure: Time (hours) taken from treatment start till body temperature dropping to normal
timeFrame: time length( hours) from treatment starting to the time that body temperature drop to normal 37.0 degree for 12 hours
measure: Time (hours) taken from disease onset till body temperature dropping to normal
timeFrame: time length (hours) from the disease onset (the starting of fever) till the time that body temperature dropped to normal (37.0 degree) and lasting for at least 12 hours
measure: Top body temperature at the 24th hour, 48th hour and the 72th hour from treatment starting.
timeFrame: from starting of treatment to the 24th hour, 48th hour, and the 72th hour
Secondary outcomes:
measure: adverse digestive tract symptoms
timeFrame: from start of treatment to discharge
measure: abnormal blood routine
timeFrame: from the start of treatment to discharge test
measure: abnormal Urine routine
timeFrame: from the start of treatment to discharge
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Children's Hospital of Fudan University
Study officials:
References:
Clinical trial NCT02855151: EUS for Gastrointestinal Disorders: a Registry
Official title: EUS for Gastrointestinal Disorders: a Registry
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: GI Tract Disorders
Pancreatic Disorders
EUS
Keywords: EUS
Lead sponsor: Istituto Clinico Humanitas
Sponsor class: OTHER
First posted: 2016-08-04
Enrollment: 10000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients submitted to diagnostic or therapeutic EUS

Brief summary: The aim of the EUS registry is to record information about Endoscopic Ultrasound (EUS) on the management of gastrointestinal disease. The registry will evaluate efficacy, safety and technical success of the Endoscopic Ultrasound (EUS). Design is retrospective and prospective registry study.


Eligibility criteria: Inclusion Criteria:

* All patients submitted to EUS,
* Informed consent.

Exclusion Criteria:

* Age less than 18 y
* Patient who did not give the consent to the processing of personal data.

Primary outcomes:
measure: Number of participants with treatment-related adverse events
timeFrame: 2 days
Secondary outcomes:
measure: Diagnostic yied of elastography during EUS
timeFrame: 0 Day
measure: Diagnostic yied of Contrast-Enhanced Endoscopic Ultrasonography
timeFrame: 0 Day
measure: Tissue acquisition during EUS
timeFrame: 0 Days
Other outcomes:
Locations:
city: Rozzano
country: Italy
facility: Endoscopy Unit, Humanitas Research Hospital
state: Milano
Study officials:
affiliation: Humanitas University
name: Alessandro Repici, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Humanitas Cancer Center
name: Silvia Carrara, MD
role: STUDY_DIRECTOR
References:
citation: Carrara S, Di Leo M, Grizzi F, Correale L, Rahal D, Anderloni A, Auriemma F, Fugazza A, Preatoni P, Maselli R, Hassan C, Finati E, Mangiavillano B, Repici A. EUS elastography (strain ratio) and fractal-based quantitative analysis for the diagnosis of solid pancreatic lesions. Gastrointest Endosc. 2018 Jun;87(6):1464-1473. doi: 10.1016/j.gie.2017.12.031. Epub 2018 Jan 9.
Clinical trial NCT05316051: Effect of Different Foot Orthosis Inverted Angles on Walking Kinematics in Females With Flexible Flatfeet
Official title: Effect of Different Foot Orthosis Inverted Angles on Walking Kinematics in Females With Flexible Flatfeet
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Flexible Flatfoot
Lead sponsor: University of Sharjah
Sponsor class: OTHER
First posted: 2022-04-07
Enrollment: 31
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Inverted orthosis is a type of rigid foot orthosis that was designed to aid in controlling high degrees of foot pronation. It is essential to administer patients foot orthoses with different inverted angles, with higher angles prescribed when greater reduction of foot pronation is indicated. However, there is shortage of clinical knowledge regarding the inverted angle in terms of biomechanical changes. The aim of this study is to investigate the effect of different inverted angles of foot orthoses on the walking kinematics in females with flexible flatfeet.


Eligibility criteria: Inclusion Criteria:

* Females
* Within the age group of 18-35 years
* Asymptomatic flexible flatfeet
* Resting Calcaneal Stance Position angle of ≥ 4° in valgus in both feet (bilateral)

Exclusion Criteria:

* Previous surgery of the lower limbs or spine that might affect the performance of the study procedures
* Any severe medical or musculoskeletal conditions that may have affected the lower limbs
* Fixed flatfoot deformity
* Leg length discrepancy (\> 1cm)
* Pregnancy

Primary outcomes:
measure: Lower limb kinematics
timeFrame: Through study completion, an average of 1 year.
Secondary outcomes:
Other outcomes:
Locations:
city: Sharjah
country: United Arab Emirates
facility: University of Sharjah
Study officials:
affiliation: University of Sharjah
name: Fatma A. Hegazy, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06500351: Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Postpartum. Hypertension
Official title: Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum Hypertension.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum Hypertension
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-07-15
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who were 18 years or above, and have a diagnosis of postpartum hypertension

Brief summary: This is an observertional study aimed at Study the association between Renalase(rs10887800) Genotyping \& Leucocytes telomere length in patients with postpartum hypertension whether new onset( denovo) or persistent following pregnancy complicated by hypertension.


Eligibility criteria: Inclusion Criteria:

* Patients who are18 years or above, and have a diagnosis of postpartum hypertension(regardless of where they received their antenatal care) attended to Sohag university hospitals

Exclusion Criteria:

* All pregnant women with medical disorders in pregnancy other than Hypertensive disorders during pregnancy (e.g., sickle cell disease, heart disease, kidney and other connective tissues disorders) will be excluded from the study. Also we excluded measurements taken during scheduled or unscheduled surgical encounters given potential for interaction with anesthetic agents

Primary outcomes:
measure: Renalase(rs10887800) Genotyping
timeFrame: 1 year
Secondary outcomes:
measure: Leucocytes telomere length
timeFrame: 1 year
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag university hosoital
Study officials:
affiliation: Sohag University
name: Amera Morad Foad, assistant professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03961451: Number of Weekly Steps, Fatigue, Quality of Life, Well-being During Cancer Treatment: Impact of Recommendations Strengthened by the Provision of Web Interface and Tele-coaching.
Official title: Number of Weekly Steps, Fatigue, Quality of Life, Well-being During Cancer Treatment: Impact of Recommendations Strengthened by the Provision of Web Interface and Tele-coaching.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer, Treatment-Related
Keywords: pedometer
Lead sponsor: Institut Paoli-Calmettes
Sponsor class: OTHER
First posted: 2019-05-23
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All cancer pathologies, all treatments. Provided that the patient is fit for walking.

Brief summary: study to correlate this level of objective physical activity with the levels of fatigue and quality of life in cancer patient being treated.

Detailed description: Study to objectify the level of physical activity of patients by a tool, often used in the global population: the pedometer. Several measurements per questionnaire also will be carried out repeatedly (weekly) in order to correlate this level of objective physical activity with the levels of fatigue and quality of life. The hypothesis we formulate is as follows: the number of weekly steps is negatively correlated with the level of fatigue, positively with the quality of life and well-being.

Eligibility criteria: Inclusion Criteria:

* Patients being treated, Medical Day Hospital / HAD

Exclusion Criteria:

* Inability to walk declared by an site medical doctor

Primary outcomes:
measure: Life satisfaction
timeFrame: 2 months
measure: Positive and negative affects measurement
timeFrame: 2 months
measure: Fatigue
timeFrame: 2 months
measure: Quality of Life
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Institut Paoli Calmettes
state: Bouches Du Rhone
Study officials:
affiliation: Institut Paoli-Calmettes
name: Maria Cappiello, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Villaron C, Cury F, Eisinger F, Cappiello MA, Marqueste T. Telehealth applied to physical activity during cancer treatment: a feasibility, acceptability, and randomized pilot study. Support Care Cancer. 2018 Oct;26(10):3413-3421. doi: 10.1007/s00520-018-4191-4. Epub 2018 Apr 19.
Clinical trial NCT05948254: Utilized Scan Body Technique For Triple Function
Official title: Utilized Scan Body Technique For Jaw Relation Registration And Face Scan Alignment (Triple Function Scan Body)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Digital Technology
Dental Implant
Occlusion
Keywords: Jaw relation
Scan body
Full arch dental implants
Lead sponsor: Ain Shams University
Sponsor class: OTHER
Collaborators: name: Assiut University
First posted: 2023-07-17
Enrollment: 15
Sex: ALL
Minimum age (years): 22
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Triple Function Scan Body
Primary purpose: TREATMENT

Brief summary: A triple function scan Body were done on healed dental implant, thus simplifying the workflow for full arch cases and reducing the number of visits to only 3 visits. In this technique, scan bodies were utilized for implant position scanning, facial scan alignment and as stoppers for jaw relation capturing as scan bodies were used as stoppers for jaw relation registration.

Detailed description: The present article describes a novel technique for merging a patient's facial scan with implant scan body and in the same time utilizing the same scan body for recording the jaw relation in only one visit. As a result, a facially driven full-arch implant-supported interim prosthesis can be fabricated first followed by the final restoration in a simplified approach. The aim of this study is to determine whether there is a difference between virtual design and reality using scan body technique (triple function scan body which reflects the accuracy of the scanning protocol. The null hypothesis established that there was consistency between the virtual design and prosthesis in patient's mouth. The scan body was placed in the edentulous arch in the jaw scan step so that bite registration would be easier for the intraoral scanner (IOS) in order to be able to capture both the teeth of the antagonist and part of the scan body in the edentulous jaw simultaneously.

Eligibility criteria: Inclusion Criteria:

* patient had at least one edentulous arch with at least 5 osseointegrated implants with healing period of 3 months after surgical procedure.
* Implants are stable
* Systemically free

Exclusion Criteria:

* Smokers
* Uncooperative patients

Primary outcomes:
measure: percentage of consistency in simultaneous contacts in maximal intercuspal position
timeFrame: 2 months following the final prosthesis
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
state: Abbassia
Study officials:
affiliation: Associate Professor Faculty of Dentistry, Ain Shams University
name: Doaa Adel-Khattab, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00347854: Fluorophotometry Evaluation of Lubricant Eye Drops
Official title: Fluorophotometry Evaluation of Lubricant Eye Drops FID 105783
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Normal, healthy eyes (other than correction for visual acuity)
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2006-07-04
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The objective of this study is to evaluate the safety and efficacy of exaggerated use of Lubricant Eye Drops in a population of normal subjects by measuring corneal epithelial permeability to fluorescein.


Eligibility criteria: Inclusion Criteria:

* Ages 18 and over

Exclusion Criteria:

* No sodium fluorescein corneal staining at Screening Visit

Primary outcomes:
measure: Epithelial permeability to fluorescein
Secondary outcomes:
measure: tear turnover rate
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Alcon
state: Texas
Study officials:
affiliation: Alcon Research
name: Mike Christensen
role: STUDY_DIRECTOR
References:
citation: http://www.aaopt.org/evaluation-new-preservation-system-corneal-barrier-function
Clinical trial NCT01125254: Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
Official title: Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Thalassemia Major
Keywords: thalassemia major
calcium channel blockade
magnetic resonance imaging
Lead sponsor: University of Campinas, Brazil
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2010-05-18
Enrollment: 10
Sex: ALL
Minimum age (years): 6
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study aims to investigate the use of amlodipine, a drug that blocks the uptake of calcium into cells, in the prevention and treatment of iron overload in patients with thalassemia major. Since iron uses the same calcium channels to enter the heart, pancreas and other organs, blocking these channels might help to prevent the accumulation of iron in these tissues. The study will follow 10 patients with thalassemia major: 5 will openly receive amlodipine and 5 will serve as controls, not receiving any additional drugs. Patients will be monitored through one year with an additional year of follow up after the group using amlodipine stops its use. Monitoring will occur through the measurement of blood ferritin as well as live and heart T2\* by MRI.


Eligibility criteria: Inclusion Criteria:

* patients with thalassemia major over 6 years of age in use of iron chelating therapy.

Exclusion Criteria:

* pregnancy;
* advanced heart failure with NYHA III/IV or LVEF \< 35%;
* formal contra-indications to an MRI study;
* patient with advanced heart block.

Primary outcomes:
measure: Myocardium T2*
timeFrame: 12 months
Secondary outcomes:
measure: Liver T2*
timeFrame: 24 months
measure: Heart volumes
timeFrame: 24 months
measure: Left ventricle ejection fraction
timeFrame: 24 months
measure: Serum ferritin
timeFrame: 24 months
measure: Myocardium T2*
timeFrame: 6-18-24 months
Other outcomes:
Locations:
city: Campinas
country: Brazil
facility: University of Campinas
state: SP
Study officials:
affiliation: University of Campinas, Brazil
name: Juliano L Fernandes, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03123354: Calibration and Validation of Masimo's O3 Regional Oximetry Device in Neonates, Infants and Children
Official title: Calibration and Validation of Masimo's O3 Regional Oximetry Device in Neonates, Infants and Children Undergoing Cardiac Catherization
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Surgery
Lead sponsor: Masimo Corporation
Sponsor class: INDUSTRY
First posted: 2017-04-21
Enrollment: 44
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The study will collect cerebral oximetry data from pediatric and neonatal subjects using the Masimo O3 regional oximetry device, for the purposes of device calibration and validation.


Eligibility criteria: Inclusion Criteria:

* Pediatric patients undergoing cardiac catheterization procedure for treatment or diagnosis of cardiovascular disease
* 1 day to less than 18 years of age
* Weight between 3.5 and 40 kg
* Parental or legal guardian consent and subject assent

Exclusion Criteria:

* Failure to obtain written consent
* Equal or more than 18 years in age
* Weight more than 40kg or less than 3.5kg
* Jaundice with bilirubin levels higher than the reference range
* Subject has skin abnormalities affecting the digits such as psoriasis, eczema, angioma, scar tissue, burn, fungal infection, substantial skin breakdown, nail polish or acrylic nails that would prevent motioning of SpO2 levels during the study or placement of cerebral oximeter

Primary outcomes:
measure: Accuracy of Sensor by Arms Calculation of Percent rSO2
timeFrame: One visit; up to 4 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University
state: California
Study officials:
References:
Clinical trial NCT02871154: Extending the hCG OPU Interval
Official title: Extending the Time Period Between the Injection of Chorionic Gonadotropin and Oocyte Pick-up as a Solution to Low Rate of Mature Oocyte and Poor Results in Assisted Reproduction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infertility
Lead sponsor: The Baruch Padeh Medical Center, Poriya
Sponsor class: OTHER_GOV
First posted: 2016-08-18
Enrollment: 20
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Our and others experience suggest that in some cases delaying oocyte pick up (OPU) for more than 39 hours after hCG injection may be of benefit.

We plan to apply this to 20 women in whom less than 20% of oocytes were found suitable for intracytoplasmic sperm injection. The delay will be for up to an interval of 47 hours from hCG to OPU.

Detailed description: In IVF one encounters some women in whom a low percentage of oocytes are found in the metaphase II stage upon their retrieval. Following some incidents, in our experience as well as others', where women injected hCG too early but oocytes were still retrieved with high proportion of maturity, we decided to delay OPU intentionally in women who had low percentage oocyte maturity in previous cycles.

Eligibility criteria: Inclusion Criteria: Previous 2 oocyte pick up cycles with 20% metaphase II oocytes in the cohort -

Exclusion Criteria:

No previous IVF history

-

Primary outcomes:
measure: Conception
timeFrame: Two years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Beruch Padeh Med Ctr Research Authority
name: Odeh-L'ya Katz, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00316654: Persistence of Antibody Response to N. Meningitidis Group C in Children
Official title: A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Prevention of Meningococcal Infection
Keywords: Prevention of Meningococcal Meningitis
vaccines, conjugate
immunology
child
antibody persistence
Lead sponsor: Novartis
Sponsor class: INDUSTRY
Collaborators: name: GlaxoSmithKline
First posted: 2006-04-21
Enrollment: 489
Sex: ALL
Minimum age (years): 7
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Persistence of Antibody Response to N. meningitidis Group C in Children


Eligibility criteria: Inclusion Criteria:

* healthy children

Exclusion Criteria:

* previous ascertained or suspected disease caused by N. meningitidis
* previous significant acute or chronic infections
* any other serious disease

Primary outcomes:
measure: Immunogenicity: serum antibody responses, as measured by bactericidal activity,using hBCA
Secondary outcomes:
measure: Evaluate and compare persistence of antibody response to N. meningitidis serogroup C as measured by serum bactericidal activity
measure: safety and tolerability
Other outcomes:
Locations:
city: Olsztyn, Lubartów, Kielce, Kraków, Bydgoszcz
country: Poland
city: Valencia
country: Spain
Study officials:
affiliation: Novartis Vaccines & Diagnostics
name: Novartis Vaccines Drug Information Services
role: PRINCIPAL_INVESTIGATOR
References: